potassium two pore domain channel subfamily K member 3Genealiases: DDSA · K2p3.1 · OAT1 · PPH4 · TASK · TASK-1
Q-omics provides the consensus-scored KCNK3 profile across patient tissues and cancer cell-line models. KCNK3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, KCNK3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, KCNK3 RNA expression shows 19,735 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, KIRC, and LSCC as cancer lineages where KCNK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNK3 survival associations across molecular data types. KCNK3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNK3 RNA expression–survival associations across cancer types. High KCNK3 expression shows unfavorable associations in KIRP, ACC, UVM, LUSC and BLCA, but favorable associations in LGG. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for KCNK3 RNA expression.
This table summarizes KCNK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNK3 shows lower tumor expression in BLCA, COAD, LUAD, LUSC and KICH and higher tumor expression in KIRC. The KIRC box plot shows higher KCNK3 RNA expression in tumor versus normal tissue (log2 FC = +2.654, t-test p < 0.001).
This table shows molecular features associated with KCNK3 in patient tissues and cancer cell lines. In patient samples, KCNK3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
